Fig. 5From: Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell linesAssessment of intracellular ROS and antioxidant effect on ovarian cancer celles treated with BT cisplatin combination. Flow cytometry detection of intracellular ROS in A2780 and A2780-CDDP (a) or IGROV-1 and IGROV-1-CDDP (b) cells treated with BT or cisplatin alone or in combination. Data are presented as relative-fluorescence intensities in a 2-dimensional FACS profile (standardized gating, 20,000 events). Enhanced ROS generation is shown by shift in peaks. All experiments were performed in triplicate. c and d show the effect of the antioxidant ascorbic acid on the viability (via PrestoBlue) of A2780 and A2780-CDDP (c) or IGROV-1 and IGROV-1-CDDP (d) cells treated with BT or cisplatin alone or in combination. Control (untreated) cells were considered as 100% viable against which treated cells were compared. The results represent % viability recovery when compared with 100 μM BT-treated cells. Data were expressed as means ± SD of triplicate experiments. Comparisons between BT-cisplatin-treated in presence of ascorbic acid vs. combination-treated in the absence of ascorbic acid for each cell line were performed using Student’s t–test. Asterisks (*) indicate p < 0.05Back to article page